Abecma (idecabtagene vicleucel) / BMS - LARVOL DELTA

Real World Comparison of CAR T-Cell and Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma (HOPA 2026) - " This single-center, retrospective study will include adult patients (≥18 years) with RRMM who received BCMA-directed CAR T-cell therapy with idecabtagene vicleucel or ciltacabtagene autoleucel or BiTE therapy with teclistamab, elranatamab, and talquetamab between March 1, 2021, and February 1, 2025. This study seeks to characterize and compare real-world clinical outcomes and toxicity profiles associated with BCMA-directed CAR T-cell therapy and bispecific antibody therapy in patients with relapsed or refractory multiple myeloma. Final results will be presented at the 2025 HOPA Annual Conference."

Bispecific • CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

Idecabtagene vicleucel manufacturing and clinical value of out of specification products in relapsed and refractory MM. (PubMed, Blood Adv) - P | "ORR was 75.4% (95% CI, 63.1-85.2) and CRR was 35.4% (95% CI, 23.9-48.2). The manufacturing success of ide-cel is reliable and consistently high, and when OOS ide-cel products emerged, they demonstrated consistent clinical efficacy and safety."

Journal • Hematological Malignancies • Inflammation • Multiple Myeloma • Oncology • TNFRSF9

Real-World Experience with Approved CAR T-Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in 1272 Relapsed/Refractory Multiple Myeloma Patients. (PubMed, Cancers (Basel)) - " In these real-world cohorts, both approved CAR T-cell therapies demonstrated favorable survival outcomes. While the incidence of severe hematologic and immune-related toxicities was high, these findings are compatible with published data from clinical trials and it seems that the clinical utility of these drugs overcomes the adverse safety profile."

Journal • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Oncology • Renal Disease

No impact of dexamethasone on CAR-T cell expansion in vitro and in patients with RRMM (AACR 2026) - "However, in patients with large B-cell lymphoma treated with axicabtagene ciloleucel in ZUMA-1, prophylactic steroids did not hinder CAR-T cell expansion (Cohort 6; Oluwole et al., 2021)...For these in vitro studies, surrogate versions for anito-cel (D-Domain), cilta-cel (VHH) and idecabtagene vicleucel (scFV) were generated and the impact of Dex on CAR-T cell phenotype and functionality was assessed...While Dex did not impact CAR-T cell expansion (D-Domain 4.8 vs 4.4; VHH 5.4 vs 4.3; scFV 5.3 vs 4.9 fold expansion), Dex treatment decreased IL-2 production, in vitro, making it an effective CRS treatment.While increased ALC and rapid CAR-T cell expansion within the first 28 days has been identified as a biomarker for delayed neurotoxicities, these data suggest that high dose steroids may not be an efficacious intervention for ALC restraint. Instead, Dex treatment is likely to curb proinflammatory cytokines and thus is an appropriate intervention for CRS management."

CAR T-Cell Therapy • IO biomarker • Preclinical • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • CD4 • CD8

Impact of neighborhood disadvantage, travel distance, and travel time on clinical outcomes of multiple myeloma patients treated with idecabtagene vicleucel (AACR 2026) - "In MM patients treated with ide-cel, most lived in less DN yet faced significant TD/TT. The marked travel burden overall and the worse responses and inferior OS in patients living in more DN highlight the need to address systemic barriers to improve CAR T access and outcomes."

Clinical • Clinical data • Hematological Malignancies • Multiple Myeloma • Oncology

Non-canonical CAR T cell states correlate with durable therapeutic responses in multiple myeloma patients (AACR 2026) - "Prior studies have shown that specific states of CAR T cells, immature myeloma phenotype and hostile tumor microenvironment (TME) are associated with rapid relapse, but much remains to be elucidated regarding how CAR T cells evolve, persist and interact with host immunity over time in patients with distinct clinical outcomes. We acquired longitudinal bone marrow (BM) and peripheral blood mononuclear cells (PBMC) samples from 22 RRMM patients receiving 4 different anti-BCMA CAR T products, including cilta-cel (n=7), ide-cel (n=5), BB21217 (n=1) and orva-cel (n=9). Favorable clinical outcomes in RRMM patients are associated with greater expansion and persistence of CAR T. Durable responses are also associated with non-canonical CAR T cell states as well as a less immunosuppressive tumor microenvironment. These results provide insights into the determinants of durable clinical responses with anti-BCMA CAR T cells for RRMM."

CAR T-Cell Therapy • Clinical • IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • NFKB1

Non-ICANS Neurologic Toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients. (PubMed, Blood Adv) - "Incidence differed significantly by product, with a significantly higher frequency of NINTs following ciltacabtagene autoleucel (cilta-cel) compared with idecabtagene vicleucel (ide-cel) (4.6% vs 0.5%; p=0.001) and experimental BCMA-directed constructs (4.6% vs 0.3%; p=0.02). This meta-analysis establishes that NINTs are a rare but important toxicity following BCMA-directed CAR-T therapy, particularly cilta-cel. Standardized definitions and improved reporting of NINTs are needed to better characterize risk and inform surveillance strategies."

Journal • Retrospective data • Hematological Malignancies • Inflammation • Multiple Myeloma • Oncology

OUTCOME OF CAR-T CELL THERAPY IN OLDER PATIENTS. A STUDY FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY (EBMT 2026) - "Disease progression accounted for 75.6% and 71.4% of deaths in NHL and MM.Multivariable analyses showed that treatment with axi-cel was associated with superior OS (HR 1.28, 95% CI:1.07–1.53; p=0.006), PFS (HR 1.41, 95% CI: 1.20–1.64; p<0.001), and lower relapse incidence (RI) compared with axi-cel...In the MM subgroup, the use of ide-cel was associated with worse PFS (HR: 2.52, 95% CI: 1.19–5.30; p=0.02) and RI, while an ECOG≥1 was associated with shorter OS (HR: 2.80, 95% CI: 1.35–5.79; p=0.006), PFS (HR: 2.54, 95% CI: 1.49–4.33; p<0.001) and higher RI. In this large real-world cohort of patients aged ≥70 years, CAR T-cell therapy showed marginally higher NRM and lower RI compared with younger populations in other studies. This suggests efficacity and safety of CAR-T in older populations."

CAR T-Cell Therapy • Clinical • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Transplantation

ANTIBIOTIC TIMING AND IMPACT ON SURVIVAL OUTCOMES IN ANTI-CD19 AND ANTI-BCMA CAR-T CELL THERAPY (EBMT 2026) - "Particularly, PIM (piperacillin-tazobactam, imipenem, meropenem) are implicated with poor outcomes...CD19 products included lisocabtagene maraleucel, tisagenlecleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel. BCMA products included idecabtagene vicleucel and ciltacabtagene autoleucel...Post CAR-T antibiotics were largely fourth generation cephalosporins such as cefepime, with vancomycin... Exposure to antibiotics in 30 days pre-CAR-T is associated with worse OS, even when adjusted for age, prior lines of therapy, and infection rate. Post-CAR-T antibiotics did not have an effect on PFS, OS or progression at first PET-CT scan. Clinicians should be judicious with antibiotic exposure in the 30 days prior to CAR-T therapy."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

HYPOFIBRINOGENEMIA AND SYSTEMIC INFLAMMATION FOLLOWING BCMA-DIRECTED CAR-T THERAPY: A RETROSPECTIVE STUDY (EBMT 2026) - " In this single-center, retrospective study, 71 adult multiple myeloma patients treated with Cilta-cel, Ide-cel, or ARI-0002h between 2020 and 2025 were analyzed. Hypofibrinogenemia is frequent after BCMA-directed CAR-T therapy and reflects the systemic inflammatory response rather than isolated hemostatic dysfunction. Its severity is moderately inversely correlated with CRS grade, CRS duration, and cumulative anti–IL-6 therapy, without significantly increasing bleeding risk. These results support the concept of a unified inflammatory syndrome in CAR-T recipients, with fibrinogen serving as a measurable marker of inflammatory burden."

CAR T-Cell Therapy • IO biomarker • Retrospective data • Hematological Disorders • Hematological Malignancies • Immunology • Inflammation • Multiple Myeloma • Systemic Inflammatory Response Syndrome

FLUDARABINE EXPOSURE IMPACTS BCMA-DIRECTED CAR-T THERAPY EFFICACY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (EBMT 2026) - "Background: Fludarabine (Flu) dosing is based on the body surface area. Flu AUC varies across CrCl despite standard dose adjustments. Higher Flu AUC is associated with improved CAR-T efficacy, which was particularly notable in cilta-cel, potentially suggesting product-specific differences between BCMA-directed CAR-T therapies. However, limited ide-cel sample size may have reduced the power to detect an effect."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

REAL-WORLD COMPARISON OF STANDARD-OF-CARE IDECABTAGENE VICLEUCEL AND CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE-MYELOMA: A STUDY ON BEHALF OF THE CTIWP AND THE CMWP OF THE EBMT (EBMT 2026) - "This large real-world comparison of anti-BCMA CAR T-cell therapy for RRMM demonstrates that use of cilta-cel translates to superior efficacy and PFS. Regarding safety, there was no difference in non-relapse mortality between treatment groups. The higher rate of CRS, (including grade>=3), in the ide-cel group, could be related to the fact that patients in the cilta-cel cohort were treated more recently with improvements in CRS prevention and treatment over time."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Inflammation • Multiple Myeloma

HYPOFIBRINOGENEMIA AND SYSTEMIC INFLAMMATION FOLLOWING BCMA-DIRECTED CAR-T THERAPY: A RETROSPECTIVE STUDY (EBMT 2026) - " In this single-center, retrospective study, 71 adult multiple myeloma patients treated with Cilta-cel, Ide-cel, or ARI-0002h between 2020 and 2025 were analyzed. Hypofibrinogenemia is frequent after BCMA-directed CAR-T therapy and reflects the systemic inflammatory response rather than isolated hemostatic dysfunction. Its severity is moderately inversely correlated with CRS grade, CRS duration, and cumulative anti–IL-6 therapy, without significantly increasing bleeding risk. These results support the concept of a unified inflammatory syndrome in CAR-T recipients, with fibrinogen serving as a measurable marker of inflammatory burden."

CAR T-Cell Therapy • IO biomarker • Retrospective data • Hematological Disorders • Hematological Malignancies • Immunology • Inflammation • Multiple Myeloma • Systemic Inflammatory Response Syndrome

ANTIBIOTIC TIMING AND IMPACT ON SURVIVAL OUTCOMES IN ANTI-CD19 AND ANTI-BCMA CAR-T CELL THERAPY (EBMT 2026) - "Particularly, PIM (piperacillin-tazobactam, imipenem, meropenem) are implicated with poor outcomes...CD19 products included lisocabtagene maraleucel, tisagenlecleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel. BCMA products included idecabtagene vicleucel and ciltacabtagene autoleucel...Post CAR-T antibiotics were largely fourth generation cephalosporins such as cefepime, with vancomycin... Exposure to antibiotics in 30 days pre-CAR-T is associated with worse OS, even when adjusted for age, prior lines of therapy, and infection rate. Post-CAR-T antibiotics did not have an effect on PFS, OS or progression at first PET-CT scan. Clinicians should be judicious with antibiotic exposure in the 30 days prior to CAR-T therapy."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

OUTCOME OF CAR-T CELL THERAPY IN OLDER PATIENTS. A STUDY FROM THE EBMT TRANSPLANT COMPLICATIONS WORKING PARTY (EBMT 2026) - "Disease progression accounted for 75.6% and 71.4% of deaths in NHL and MM.Multivariable analyses showed that treatment with axi-cel was associated with superior OS (HR 1.28, 95% CI:1.07–1.53; p=0.006), PFS (HR 1.41, 95% CI: 1.20–1.64; p<0.001), and lower relapse incidence (RI) compared with axi-cel...In the MM subgroup, the use of ide-cel was associated with worse PFS (HR: 2.52, 95% CI: 1.19–5.30; p=0.02) and RI, while an ECOG≥1 was associated with shorter OS (HR: 2.80, 95% CI: 1.35–5.79; p=0.006), PFS (HR: 2.54, 95% CI: 1.49–4.33; p<0.001) and higher RI. In this large real-world cohort of patients aged ≥70 years, CAR T-cell therapy showed marginally higher NRM and lower RI compared with younger populations in other studies. This suggests efficacity and safety of CAR-T in older populations."

CAR T-Cell Therapy • Clinical • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Transplantation

FLUDARABINE EXPOSURE IMPACTS BCMA-DIRECTED CAR-T THERAPY EFFICACY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (EBMT 2026) - "Background: Fludarabine (Flu) dosing is based on the body surface area. Flu AUC varies across CrCl despite standard dose adjustments. Higher Flu AUC is associated with improved CAR-T efficacy, which was particularly notable in cilta-cel, potentially suggesting product-specific differences between BCMA-directed CAR-T therapies. However, limited ide-cel sample size may have reduced the power to detect an effect."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

LTFU: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (clinicaltrials.gov) - P2/3 | N=312 | Recruiting | Sponsor: Celgene | N=214 ➔ 312

Enrollment change • Pediatrics

Predictors of 30-day readmissions post-CAR-T in patients with relapsed/refractory multiple myeloma using the United States nationwide readmission database. (PubMed, Ann Hematol) - "This is a retrospective cohort study using the National Readmission Database (NRD) aimed at evaluating hospital outcomes, economic burden, and readmission risks for ide-cel and cilta-cel in a real-world cohort of RRMM patients treated across various hospitals in the USA. These findings highlight the significant clinical and economic burden of post-CAR-T care, despite the transformative impact of these therapies on outcomes for RRMM. The online version contains supplementary material available at 10.1007/s00277-026-06927-z."

Journal • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Oncology

Irreversible parkinsonism after idecabtagene vicleucel: long-term outcome of a rare BCMA CAR T-cell neurotoxicity. (PubMed, Leuk Lymphoma) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. (PubMed, Blood Adv) - P | "These results underscore the potential benefits of diversifying targets in relapse post-ide-cel treatment strategies. This trial was registered at www.clinicaltrials.gov as #NCT04328298."

Journal • Real-world evidence • Hematological Malignancies • Multiple Myeloma • Oncology

Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the "STEM" (Sequential T Cell-Engagement for Myeloma) trial (ASH 2025) - P2 | "Median number of prior lines was 4 (2-10), with 74% triple-class refractory, 11% prior BCMA therapy, and 11% prior talquetamab. Twenty-five (93%) received cilta-cel and 2 (7%) ide-cel... To date, cevostamab consolidation starting 10-12 weeks post-CAR T cell infusion at 3.6mgsingle step-up and 132mg q3wk target dose appears feasible and well-tolerated in heavily-pretreatedRRMM, with low rates of non-hematologic G3/4 TEAE's, including infections. Preliminary efficacy appearspromising, with over 90% showing sustained MRD-negative CR at 1 year. Analyses and follow-up areongoing."

CAR T-Cell Therapy • Clinical • IO biomarker • P2 data • Ataxia • Autoimmune Hepatitis • Cough • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Infectious Disease • Movement Disorders • Multiple Myeloma • Musculoskeletal Pain • Neutropenia • Respiratory Diseases • Thrombocytopenia

Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma (ASH 2025) - P2 | "10/43 (23%) had ≥1 prior BCMA-directed therapies (BCMA-DT) (4 bela-maf, 2cilta-cel, 6 ide-cel)...3/3 pts with PD who received talquetamab (Tal) as next therapyresponded (2 VGPR, 1 CR)... In this preliminary analysis, discontinuation of Tec after 6-9m yields outcomes comparableto historical expectations with continuous therapy with estimated median FFS of 73% at 12m post-discontinuation in a cohort with 23% prior BCMA-DT. Early instances of PD (<6m after Tecdiscontinuation) that were evaluable exhibited BCMA loss and were thus unlikely due to Tecdiscontinuation. Response to Tal immediately after failing Tec re-treatment and low sBCMA at PD furthersuggest resistance due to BCMA loss/mutation as an important mechanism of PD even months after Tecdiscontinuation."

Clinical • IO biomarker • Hematological Malignancies • Multiple Myeloma • SDC1

Idecabtagene vicleucel (ide-cel) provides progression-free survival (PFS) and overall response rate (ORR) benefits in older patients with relapsed or refractory multiple myeloma, according to a subgroup analysis of the phase 3 KarMMa-3 trial. (Physician’s Weekly) - "Regardless of age, all patients achieved a higher ORR in the ide-cel group compared with the standard regimen group. Among older patients, the ORR was 81.6% (95% CI, 70.8%-92.5%) with ide-cel versus 48.1% (29.3%-67.0%) with standard regimens (P<0.01). Among younger patients, the ORR was 68.8% (95% CI, 62.4%-75.1%) with ide-cel versus 41.0% (31.5%-50.4%) with standard regimens (P<0.0001). Progression-free survival followed a similar trend. The median PFS for older patients was 18.9 months (95% CI, 12.1-24.5) with ide-cel versus 5.7 months (2.2-12.2) with standard regimens (P<0.01), while the median PFS for younger patients was 12.5 months with ide-cel (95% CI, 11.2-15.4) versus 4.2 months (3.5-5.7) with standard regimens (P<0.0001)."

P3 data • Multiple Myeloma

Management of ICANS after CAR-T Therapy: Treatment Patterns and Outcomes in a Real-world Cohort from Six German Centers (EHA-EBMT-CART 2026) - "CAR-T products were Axi-cel (n=105), Brexu-cel (n=25), Tisa-cel (n=19), Liso-cel (n=8), Ide-cel (n=7), and Cilta-cel (n=1). Timing of anti-inflammatory therapy appears clinically relevant: delayed anakinra use was associated with prolonged neurotoxicity, which in turn correlated with inferior survival. These findings underscore the need for prospective trials to clarify optimal therapeutic sequencing and to harmonize ICANS management strategies."

Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Cell Lymphoma • CNS Disorders • Epilepsy • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

REAL-WORLD COMPARISON OF CRS AND ICANS SEVERITY ACROSS SIX COMMERCIAL CAR-T THERAPIES (ISPOR 2026) - "Adult patients with hematological malignancies treated with one of six FDA-approved CAR-T products (cilta-cel, ide-cel, axi-cel, brexu-cel, liso-cel, and tisa-cel) were included...ith brexucabtagene autoleucel and axicabtagene ciloleucel showing higher rates of Grade 3 neurotoxicity; however, differences were not statistically significant (χ² p>0.05)... While mild-to-moderate toxicities are common in real-world settings, specific CAR-T products have distinct toxicity profiles. Some products are linked to higher CRS incidence while others are associated with more severe neurotoxicity. These findings provide important clinical insights and highlight the need for specific management strategies to reduce severe complications."

Clinical • Cytokine release syndrome • Real-world • Real-world evidence • Hematological Malignancies